Acurx Pharmaceuticals Secures New Patent from Japanese Patent Office for DNA Polymerase IIIC Inhibitors, Expanding Antibiotic Development Program
Acurx Pharmaceuticals has been granted a new patent by the Japanese Patent Office for its DNA polymerase IIIC inhibitors, which target the treatment of MRSA, VRE, and Anthrax infections. This patent is set to expire in December 2039, subject to extension, and represents a significant advancement in the ongoing development of their pre-clinical antibiotic candidate, ACX-375C.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY85353) on May 13, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。